Over-expression of EGFR in breast cancer

Chinese Journal of Cancer Research

Volumn 20, Issue 1, 2008, Pages 69-72

  Bo, Ai Hua ^a   Hou, Jin Chao ^a   Lan, Yong Hao ^a   Tian, Ya Ting ^a   Zhang, Jun Yan ^a  

^a HEBEI NORTH UNIVERSITY   (China)

Author keywords

Breast adenoma; Breast cancer; Epidermal growth factor receptor (EGFR); Immunohistochemistry

Indexed keywords

4 DIMETHYLAMINOAZOBENZENE; EPIDERMAL GROWTH FACTOR RECEPTOR; PARAFFIN;

ADULT; AGED; ARTICLE; BREAST ADENOMA; BREAST CANCER; CANCER INVASION; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION;

EID: 41149145760     PISSN: 10009604     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11670-008-0069-1     Document Type: Article

References (15)

1. Bo AH, Cheng L, Li HF, et al. Dependability of Epidermal growth factor receptor and tumor in genesis and treatment [J]. Medical Recapitulate (in Chin) 2006; 12:1238-9.
2. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy [J]. Oncologist 2002; 7:2-8.
3. Schippinger W, Dandachi N, Regitnig P, et al. The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer [J]. Am J Clin Pathol 2007; 128:630-37.
4. Xie FH, Wang RX. The research progress of the relationship between the way of EGFR family's signal transfer and breast cancer [J]. Int J Lab Med (in Chin) 2006; 27:1004-8.
5. Ahmed SM, Cohen EE. Treatment of squamous cell Carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors [J]. Curr Cancer Drug Targets 2007; 7:666-73.
6. Herbst RS, Langer CJ. Epidermal growth factor receptor as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and heck cancers [J]. Semin Oncol 2002; 29:27-36.
7. Zhang Y, Zhang YF, Bryant J, et al. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer [J]. Clin Cancer Res 2004; 10:3667-77.
8. Bianco R, Damiano V, Gelardi T, et al. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling [J]. Curr Pharm Des 2007; 13:3358-67.
9. Bonner JA, Sloan JA, Rowland KM Jr, et al. Significance of neurin-specific enolase levels before and during therapy for amall cell lung cancer[J]. Clin Cancer Res 2000; 6:597-601.
10. Hu M, Scollard D, Chan C, et al. Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [(111)In] DTPA-hEGF [J]. Nucl Med Biol 2007; 34:887-96.
11. Huang S, Armstrong EA, Benavent S, et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): conbining anti-EGFR antibody with tyrosine kinase inhibitor [J]. Cancer Res 2004; 64:5355-62.
12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J]. N Engl J Med 2004; 350:2129-39.
13. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin[J]. J Clin Oncol 2000; 18:904-14.
14. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer [J]. Clin Cancer Res 2001; 7:1204-13.
15. Herbst RS, Hong WK. IMC-225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer [J]. Semin Oncol 2002; 29:18-30.